--- title: "Evonik wins two Pharma Excipients Awards at CPHI China 2026 in Shanghai; Leadership in advanced drug delivery" sdDatePublished: "2026-06-17T11:08:00Z" source: "https://www.evonik.com/en/news/press-releases/2026/06/evonik-wins-two-pharma-excipients-awards-at-cphi-china-2026.html" topics: - name: "healthcare industry" identifier: "medtop:20001354" locations: - "Shanghai" - "Germany" - "China" - "Essen" --- Evonik wins two Pharma Excipients Awards at CPHI China 2026 in Shanghai; Leadership in advanced drug delivery Evonik wins two Pharma Excipients Awards at CPHI China 2026 Evonik wins two Pharma Excipients Awards at CPHI China 2026 EUDRAGIT® and EUDRACAP® colon named winner in “Market Impact” and “Advanced Technology” categories Reinforcing Evonik’s global leadership in advanced drug delivery technologies Supporting China’s transition toward high-quality, innovation-driven pharmaceutical development Evonik has received two Pharma Excipients Awards at CPHI China 2026 in Shanghai. The company won the “Market Impact” award for its EUDRAGIT® functional film coating polymers and the “Advanced Technology” award for its EUDRACAP® colon-targeting functional capsules . This dual achievement highlights Evonik’s global leadership in advanced drug delivery technologies and underscores its commitment to supporting the transformation of China’s pharmaceutical industry toward higher quality standards and innovation-driven growth. “It is a great privilege to receive two awards,” said Yu Ding, Business Director of Evonik Health Care Greater China. “Building on this milestone, we look forward to strengthening collaboration with our customers in China to accelerate the development of differentiated drug products and deliver greater benefits to patients.” Evonik’s “Market Impact” award-winning EUDRAGIT® functional film coating polymers are widely recognized as an industry standard for oral controlled drug delivery. Used in more than 80 countries and cited in over 23,000 patents, EUDRAGIT® was introduced to China in the 1990s. Since then, it has played a pivotal role in advancing solid oral dosage form technologies. Its broad adoption in locally developed controlled- and sustained-release formulations has contributed to improved product quality and supported Chinese pharmaceutical companies in their transition from high-quality generics to innovative, proprietary drug delivery solutions. Recognized in the “Advanced Technology” category, EUDRACAP® colon is the first ready-to-fill functional capsule on the market to target the ileo-colonic region. It enables the safe and effective oral delivery of sensitive active pharmaceutical ingredients (APIs) while helping to accelerate drug development timelines. The capsules are compatible with powders, pellets, and granules, and can be easily processed using standard capsule filling equipment. The Pharma Excipients Awards, a flagship category of the CPHI China Celebration Awards, honor breakthrough excipient technologies and high-potential products that elevate industry standards and promote high-quality pharmaceutical development. EUDRACAP® colon also gained international acclaim at the CPHI Pharma Awards in Frankfurt in 2025. Evonik Health Care has been a leader in advanced drug delivery for decades, supporting pharmaceutical companies worldwide with comprehensive services for the development of complex oral and parenteral drug products. This includes pharmaceutical excipients, formulation development and the manufacture of clinical samples, as well as commercial drug products. Furthermore, the business serves as a CDMO for APIs and intermediates and has a strong focus on growth fields such as lipid-based mRNA and gene delivery, and cell culture solutions for biopharma applications. Spoken languages: german , english , polish Spoken languages: german , english Evonik goes beyond the boundaries of chemistry with its combination of innovative strength and leading technological expertise. The global chemical company, headquartered in Essen, Germany, is active in more than 100 countries and generated sales of €14.1 billion and earnings (adjusted EBITDA) of €1.9 billion in 2025. The common motivation of the approximately 31,000 employees: to provide customers with a decisive competitive advantage with tailor-made products and solutions as a superforce for industry, thereby improving people's lives. In all markets. Every day. The Custom Solutions segment focuses on innovation-driven, tailor-made solutions for customers in specific growth markets. These solutions include additives for coatings, adhesives and sealants, polyurethane foams and lubricants, catalysts, and ingredients for the cosmetics, cleaning and pharmaceutical industries. In 2025, the segment generated sales of €5.4 billion with around 9,500 employees. In so far as forecasts or expectations are expressed in this release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release. Evonik Industries AG Rellinghauser Straße 1-11 45128 Essen Germany Phone +49 201 177-01 www.evonik.com Supervisory Board Bernd Tönjes, Chairman Executive Board Christian Kullmann, Lauren Kjeldsen, Dr. Claudine Mollenkopf, Michael Rauch, Thomas Wessel Registered Office is Essen Register Court Essen Local Court Commercial Registry B 19474 EUDRAGIT® functional film coating polymers EUDRACAP® functional, ready-to-fill HPMC capsules Head of Market Communications Health Care